QUOTE AND NEWS
The Times of India  Jan 17  Comment 
Swiss pharmaceutical giant Novartis has restrained a local pharma company from making anti-diabetes drug by approaching a court because the MNC had patented the drug and is enjoying monopoly over its production and sale.
Benzinga  Jan 15  Comment 
Paycom Software, Inc. (NYSE: PAYC) surged 3.15% to $23.91. The volume of Paycom Software shares traded 2633% higher than normal. Paycom Software announced the pricing of a secondary public offering of 5,585,000 shares of its common stock by...
The Hindu Business Line  Jan 14  Comment 
Delhi High Court today sought the response of Switzerland-based drug major Novartis AG on the plea of Indian pharma firm Cipla against an order restraining it from making its respiratory diseas...
The Hindu Business Line  Jan 13  Comment 
Drugmaker Novartis India’s board of directors has approved the transfer of its over the counter (OTC) business to GlaxoSmithKline Consumer Pvt Ltd for ₹109 crore. The deal would be c...
Reuters  Jan 13  Comment 
The Delhi High Court has barred generic drugmaker Cipla Ltd from making or selling a cheaper copy of Novartis AG's respiratory drug Onbrez domestically, citing infringement of patents held by the Swiss company.
Market Intelligence Center  Jan 12  Comment 
Novartis AG (NVS) traded between $95.73 and $96.81 before closing at $96.12 Friday and presents some attractive trading opportunities today. MarketIntelligenceCenter.com’s patented algorithms selected a Apr. '15 $95.00 covered call for a net...
FiercePharma  Jan 8  Comment 
U.K. officials have decided which drugs to toss off the Cancer Drug Fund, which pays for drugs rejected by cost-effectiveness gatekeepers. Reportedly, Novartis, Sanofi and Eisai treatments are among them.
Forbes  Jan 7  Comment 
The implications extend beyond cancer drugs. Biosimilars have the potential to significantly reduce the costs of modern health care for people with all kinds of illness
FierceBiotech  Jan 7  Comment 
A group of FDA advisers unanimously recommended approval for Novartis' knockoff of a blockbuster Amgen treatment, clearing the way for what would be the first U.S. approval of a copycat biologic medicine.




 

Fuerralz? That's marvelously good to know.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki